Novartis unveiled its restructuring plans on Tuesday, June 28, but the program may also lead to job cuts, and around 8,000 employees are set to be affected. The Swiss -American multinational pharmaceutical company headquartered in Basel, Switzerland and Cambridge, Massachusetts, said that the reduction of its workforce will give them a savings of up to $1 billion by the year 2024.
As per Reuters, Novartis actually announced its restructuring program weeks before, and it has reaffirmed that it is set to let go of around 7.4% of its total workforce globally. The firm said that up to 1,400 workers based in Switzerland are also affected.
Previously, the projected job cuts were revealed by Novartis' chief executive officer, Vas Narasimhan. He explained back in April that it will be a "single digit thousands," and the company is doing this as part of a reorganization to save money.
The company shared through an email message that since the announcement, it has made good progress in the implementation of its new organizational structure. Under the program, Novartis has merged its pharmaceuticals and oncology business divisions. On the downside, this move entails the termination of some job roles throughout the organization.
"This restructuring could potentially impact 1,400 positions based in Switzerland, out of around 8,000 positions impacted globally," the company was quoted as saying in the email. The termination of workers was also confirmed by a local Swiss paper TagesAnzeiger. Currently, Novartis employs 108,000 staff worldwide, and 11,600 of them are based in Switzerland.
The restructuring comes as the company's chief Narasim is trying to bolster his efficiency credentials since Novartis is receiving huge cash windfalls that include a $20.7 billion last year from the sale of its 33% stake to its rival company, Roche.
Meanwhile, Bloomberg reported that the latest layoffs will fall heavily on the company's operations in Switzerland since it will be eliminating more than a thousand workers. The company also clarified that it has initiated consultations with employees at its HQ prior to the cutbacks.
"The new structure will be both leaner and simpler and as such the company intends to eliminate roles across the organization, subject to local information and consultation requirements," Novartis explained.


Asian Currencies Rally as Dollar Weakens, Trump-Iran Ceasefire Boosts Risk Sentiment
Goldman Sachs Cuts 2026 Copper Price Forecast Amid Global Growth Concerns
Gold Prices Drop for Third Consecutive Session Amid Iran Tensions and Inflation Fears
Xi Jinping Pushes Demand-Driven Strategy to Modernize China's Service Sector
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Britain Courts Anthropic Amid US Defense Department Dispute
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
U.S. Futures Slip as Iran Rejects Ceasefire and Trump Deadline Looms
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
U.S.-Iran Ceasefire: Fragile Truce Raises Hopes for Strait of Hormuz Peace Deal
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
US Dollar Dips as Iran Rejects Ceasefire Amid Rising Middle East Tensions
Gold Surges Near 3-Week High as Trump-Iran Ceasefire Eases Geopolitical Tensions 



